Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Jacobio Pharmaceuticals presented promising preliminary Phase I clinical trial data for its BET inhibitor JAB-8263 at the American Society of Hematology Annual Meeting. The drug showed positive results in reducing spleen volume and symptom scores in myelofibrosis patients. This development highlights Jacobio’s innovative approach in the competitive pharmaceutical landscape.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.